会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • CALCIUM ION CHANNEL MODULATORS & USES THEREOF
    • 钙离子通道调制器及其用途
    • WO2010001179A2
    • 2010-01-07
    • PCT/GB2009/050787
    • 2009-07-03
    • LECTUS THERAPEUTICS LIMITEDKHAN, Nawaz MohammedBURCKHARDT, SvenjaCANSFIELD, Julie ElaineVO, Ngoc-TriARMER, Richard EdwardBOFFEY, Raymond John
    • KHAN, Nawaz MohammedBURCKHARDT, SvenjaCANSFIELD, Julie ElaineVO, Ngoc-TriARMER, Richard EdwardBOFFEY, Raymond John
    • C07D209/12C07D209/18A61K31/404A61P13/00A61P29/00
    • C07D491/056A61K31/404C07D209/18C07D209/24C07D401/06
    • Compounds of formula (1 ), salts and pro-drugs wherein: R1, R2, R3 and R4 are hydrogen, alkyl, hydroxyalkyl, halogen, haloalkyl, alkoxy, haloalkoxy, alkoxycarbonyl, carboxyl, hydroxyl, nitro, amino, monalkylamino, dialkylamino, acylamino, alkoxycarbonylamino, alkylsulphonyl, arylsulphonyl, alkylsulphonylamino, arylsulphonylamino, aminosulphonyl or cyano, or any two of R1 to R4 that are adjacent on the ring may together represent the moiety -O-(CH 2 ) n -O- wherein n is 1 to 3; R5 is hydrogen or alkyl; R6 is hydrogen or alkyl; and X is selected from the group consisting of: (a) groups of formula OR7 wherein R7 is hydrogen or alkyl which is optionally substituted with a substituent selected from alkylsulfonylalkyl, saturated or partially unsaturated heterocyclic, alkoxy, carboxyl, nitro, amino, monalkylamino, dialkylamino, halogen, and alkoxycarbonyl, provided that when R7 is hydrogen or ethyl, then R1, R2, R3 and R4 cannot be selected from hydrogen, halogen and alkyl; and (b) groups of formula NR8R9 wherein R8 and R9 together with the nitrogen atom to which they are attached form a saturated or partially unsaturated heterocyclic group which optionally contains at least one more heteroatom selected from nitrogen, oxygen and sulphur atoms, said saturated or partially unsaturated heterocyclic group optionally further being substituted by one or more substituents selected from alkyl, halogen, haloalkyl, alkoxy, alkoxycarbonyl, carboxyl, nitro, amino, monalkylamino, dialkylamino and hydroxyl, provided that: (i) when R8 + R9 +N = piperazine, and ≥ 1 of R1 to R4 are hydrogen, hydroxyl, nitro, amino, alkylamino, dialkylamino, alkoxycarbonylamino, halogen, alkoxy or alkyl, the nitrogen atom at the 4-position of the piperazine is not alkyl substituted, (ii) when each of R1, R2, R3, R4, R5 and R6 is hydrogen, X is not unsubstituted piperazinyl or unsubstituted morpholino, (iii) when each of R1, R2, R4, R5 and R6 is hydrogen and R3 hydrogen, bromine or hydroxyl, X is not methoxy, (iv) when each of R2 and R3 is methoxy or they together represent -0-CH 2 -O- and each of R1, R4, R5 and R6 is hydrogen, X is not unsubstituted piperidine, are Cavx channel blockers and are of use in the treatment of various conditions including pain.
    • 式(1)的化合物,其盐和前药,其中:R1,R2,R3和R4是氢,烷基,羟基烷基,卤素,卤代烷基,烷氧基,卤代烷氧基,烷氧基羰基,羧基,羟基,硝基,氨基,单烷基氨基,二烷基氨基, 酰基氨基,烷氧基羰基氨基,烷基磺酰基,芳基磺酰基,烷基磺酰基氨基,芳基磺酰基氨基,氨基磺酰基或氰基,或在环上相邻的R 1至R 4中的任意两个可以一起代表-O-(CH 2)n O-部分,其中n为1至3; R5是氢或烷基; R6是氢或烷基; 并且X选自:(a)式OR7基团,其中R 7是氢或任选被选自烷基磺酰基烷基,饱和或部分不饱和杂环,烷氧基,羧基,硝基,氨基,单烷基氨基, 二烷基氨基,卤素和烷氧基羰基,条件是当R 7为氢或乙基时,则R 1,R 2,R 3和R 4不能选自氢,卤素和烷基; 和(b)式NR8R9基团,其中R8和R9与它们所连接的氮原子一起形成饱和或部分不饱和的杂环基团,其任选地含有至少一个选自氮,氧和硫原子的杂原子,所述饱和或 任选地进一步被一个或多个选自烷基,卤素,卤代烷基,烷氧基,烷氧基羰基,羧基,硝基,氨基,一烷基氨基,二烷基氨基和羟基的取代基取代的部分不饱和杂环基,条件是:(ⅰ)当R8 + R9 + 哌嗪,R1至R4中的= 1是氢,羟基,硝基,氨基,烷基氨基,二烷基氨基,烷氧基羰基氨基,卤素,烷氧基或烷基,哌嗪4-位上的氮原子不是烷基取代的,(ii) R 1,R 2,R 3,R 4,R 5和R 6中的每一个是氢,X不是未取代的哌嗪基或未被取代的吗啉代,(iii)当R 1,R 2,R 4,R 5和R 6各自为氢和R 3氢,溴或羟基 ,X不为甲氧基,(iv)当R 2和R 3各自为甲氧基或它们一起表示-O-CH 2 -O-并且R 1,R 4,R 5和R 6各自为氢时,X为未取代的哌啶,为Cavx通道 可用于治疗包括疼痛在内的各种病症。